Evidence map›Paper›PMID 39100048›Full record

ArticleCureus2024

A Case of Revelation Due to Pegfilgrastim.

Kevin T Dao, Kishan Ghadiya, Elias Inga Jaco, Rupam Sharma, Roshun Rahimi, Marah Sukkar, Moujin Adebayo, Janpreet Bhandohal, Harmanjeet Dhillon, Fowrooz Joolhar

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kevin T DaoInternal Medicine, Kern Medical, Bakersfield, USA.
Kishan GhadiyaInternal Medicine, Kern Medical, Bakersfield, USA.
Elias Inga JacoInternal Medicine, Kern Medical, Bakersfield, USA.
Rupam SharmaInternal Medicine, Kern Medical, Bakersfield, USA.
Roshun RahimiInternal Medicine, Kern Medical, Bakersfield, USA.
Marah SukkarInternal Medicine, Kern Medical, Bakersfield, USA.
Moujin AdebayoInternal Medicine, Kern Medical, Bakersfield, USA.
Janpreet BhandohalInternal Medicine, Kern Medical, Bakersfield, USA.
Harmanjeet DhillonInternal Medicine, Kern Medical, Bakersfield, USA.
Fowrooz JoolharCardiology, Kern Medical, Bakersfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pegfilgrastim is a granulocyte colony-stimulating factor used in non-myeloid cancer patients to prevent infections and neutropenic fevers. Although this medication is widely used to induce granulocytosis in pancytopenia patients, there are certain instances where such a situation can cause severe side effects. In this case, we present a patient with a history of metastatic colon cancer who is currently taking pegfilgrastim to counter the agranulocytosis caused by his chemotherapy treatment. However, the patient shortly developed localized left-sided jaw swelling, and upon further investigation, the granulocyte colony-stimulating factor revealed an underlying bacteremia. A discussion will also be held regarding the mechanism of action of how pegfilgrastim induced this patient's symptoms as well as the risks and benefits.

Indexed as

granulocyte colony-stimulating factorjaw massmedication inducedmultidisciplinaryneulastapegfilgrastim

Identifiers

PMID39100048
PMCPMC11296959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.